Synthon Biopharmaceuticals BV and MAB Discovery GmbH today announced the execution of a research and license agreement.

Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company’s development of antibody-drug conjugates (ADCs) and alternative antibody-based therapeutics. 

MAB Discovery will employ its in vivo antibody discovery technology platform, which relies on the natural immune response of rabbits followed by state-of-the-art B-cell cloning techniques. Using a novel high-throughput screening route, MAB Discovery focuses on identifying highly active antibodies with unprecedented epitope coverage, potency and species cross-reactivity which has been successful for intractable targets. This technology eliminates affinity maturation and surrogate development which are very time-consuming and often sacrifice function.

Synthon will obtain high quality antibodies in support of their strategy to create a portfolio of best-in-class antibody-based therapeutics, including ADCs.

Additional details of the transaction were not disclosed.


About Synthon

Synthon, with headquarters in Nijmegen, The Netherlands, is an international pharmaceutical company and a leader in the field of generic medicines. The company started its biopharmaceutical franchise in 2007 and is building a promising portfolio of next generation medicines. Synthon is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune diseases and oncology. Synthon products are currently approved by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon employs about 1,400 staff worldwide, and in 2013 it recorded a turnover of EUR 215 million. For more information, go to

About MAB Discovery

MAB Discovery was founded in Munich, Germany in October 2010. The team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. Funded by PPD Inc., MAB Discovery follows a collaboration-based business model as a basis for its partnerships. Because of their unique funding situation, MAB Discovery can employ flexible business models to meet the needs of their clients. For more information, go to

     Share this page

More information